US › Healthcare

Spruce Biosciences, Inc. Common Stock (SPRB)

US · Healthcare · Biotechnology

$46.26+7.23%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-12.3M
Profit YoY
+12.6%
EPS
$-8.94
EPS estimate
$-6.11

EPS came in at -8.94 against a street estimate of -6.11 — a miss of 46.3%.

Key statistics

Market cap
$118.7M
Forward P/E
0.0
P/B
3.40
Book value
$25.25
EPS (TTM)
$-35.82
52-week high
$240.00
52-week low
$7.00
50-day MA
$49.04
200-day MA
$72.73
Beta
3.34

Analyst view

Analysts rate Spruce Biosciences, Inc. Common Stock a hold (0 buy, 5 hold, 0 sell out of 5) with an average price target of $151.00.

Shareholding

Insiders
3.52%
Institutions
41.23%

Largest institutional holders

FundStake
Ikarian Capital, LLC4.41%
Millennium Management LLC4.07%
Citadel Advisors Llc2.54%
ADAR1 Capital Management LLC2.13%
Alyeska Investment Group, L.P.1.88%
Wellington Management Company LLP1.77%
BOOTHBAY FUND MANAGEMENT, LLC1.53%
Balyasny Asset Management LLC1.45%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Spruce Biosciences, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.